1. Please detail the number of patients currently prescribed Apremilast with a current primary diagnosis of: a) Psoriasis b) Psoriatic Arthritis?
2. Of the patients prescribed Apremilast in the last 12 months for Psoriasis and Psoriatic Arthritis, what number of patients received treatment with targeted small molecules or biologic therapies* prior to beginning treatment with Apremilast? (*See annex 1 for a list of small molecule/biologic therapies)
3. How many small molecule- and/or biologic-naive patients in the Trust are currently receiving a conventional non-biologic systemic therapy for Psoriasis or a conventional non-biologic disease-modifying anti-rheumatic drug (DMARD) for Psoriatic Arthritis? (e.g. methotrexate)
4. Is CCG prior-approval required for the prescribing of Apremilast? Y/N. If Yes, please tick the system you use: Blueteq □/Other □.
5. If other, what system do you use?
6. Is Apremilast listed individually or grouped with biologic therapies on the prior-approval form for Psoriasis and Psoriatic Arthritis?
7. Please provide the wording used on the CCG’s prior-approval form for the prescribing of Apremilast.
Annex 1
Abatacept (Orencia®)
Adalimumab (Amgevita®, Humira®, Hyrimoz® or Imraldi®)
Brodalumab (Siliq®)
Certolizumab (Cimzia®)
Etanercept (Benepali®)
Golimumab (Simponi®)
Guselkumab (Tremfya®)
Infliximab (Remicade®)
Ixekizumab (Taltz®)
Risankizumab (Skyrizi®)
Secukinumab (Cosentyx®)
Tildrakizumab (Ilumya®)
Tofacitinib (Xeljanz®)
Ustekinumab (Stelara®)
